Sepsis occurs when the body responds to an infection with a mix of tissue-damaging inflammation and anti-inflammatory responses. This biological storm can lead to acute organ dysfunction (severe sepsis) and dropping blood pressure that does not respond to intravenous fluids (septic shock).
Kevin Lance, a graduate student in the Desai lab, holds thin-film blood-vessel wrap being developed to deliver anti-scarring drugs.
Research in the laboratory of Tejal Desai, PhD, is creating new kinds of drug delivery devices to reduce the scarring and inflammation that can undermine stents—metal mesh tubes implanted to prop open blocked arteries, including in the heart.
New research support awarded to the UCSF School of Pharmacy by the National Institutes of Health during the 2011 fiscal year included these on-going projects by faculty in the Department of Pharmaceutical Chemistry:
Faculty members in the Department of Bioengineering and Therapeutic Sciences, UCSF Schools of Pharmacy and Medicine, share their research on the human microbiome and microfabricated drug delivery systems and their hopes for how their science will improve the health of patients.
UCSF scientists from the Department of Bioengineering and Therapeutic Sciences and UCSF School of Pharmacy Dean Mary Anne Koda-Kimble, PharmD, spoke on June 23, 2009 about how their research is aiming to make therapeutics sophisticated, highly effective, and tailored to the different needs of individuals.
Kathy M. Giacomini, PhD, chair, department of biopharmaceutical sciences and Leslie Z. Benet, PhD, professor in the same department, were both honored at the Pharmaceutical Sciences World Congress, held May 29 to June 4, 2004 in Kyoto, Japan.
Leslie Z. Benet, PhD, was named a Thomson ISI Highly Cited Researcher in December 2003. The designation means that Benet's research publications on pharmacokinetics and pharmacodynamics have been extensively cited by other scientists in their publications. Citation is an important way to measure influence in science through time.